Discover
bimekizumab (UCB4940) / UCBBimekizumab: Topline data from P3 BE COMPLETE trial (NCT03896581) for psoriatic arthritis in H2 2021 (UCB) - Feb 21, 2020 - FY 2019 Results[Screenshot]bimekizumab (UCB4940) / UCBBimekizumab: Topline data from P3b BE RADIANT trial (NCT03536884) for psoriasis in Q2 2020 (UCB) - Feb 21, 2020 - FY 2019 Results[Screenshot]bimekizumab (UCB4940) / UCBBimekizumab: Topline data from P3 BE OPTIMAL trial (NCT03895203) for psoriatic arthritis in H2 2021 (UCB) - Feb 21, 2020 - FY 2019 Results[Screenshot]Tremfya (guselkumab) / J&JThey launch a new medicine for the treatment of psoriasis [Google Translation] (Diario Panorama) - Feb 22, 2020 - "Janssen...announced that a new psoriasis drug is available in the local market . This is Guselkumab aimed at treating adult patients with moderate to severe plaque disease who are also candidates for systemic therapy. The drug was approved by the National Administration of Medicines, Food and Medical Technology (Anmat) in July last year."Taltz (ixekizumab) / Eli LillyTaltz: Protection of compound patent in US until 2026, EU until 2031 and Japan until 2030 (Eli Lilly) - Feb 20, 2020 - Annual Report 2019: Biologic data package protection in US until 2028Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly; bimekizumab (UCB4940) / UCBUCB full year report 2019 (PRNewswire.co.uk) - Feb 20, 2020 - "R&D update: UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020; Net sales break-down by core product: Cimzia® (certolizumab pegol)...net sales increased to more than € 1.7 billion, driven by continued, sustainable growth in all regions. Growth is also driven by new patient populations like women of childbearing age and people living with non-radio-graphic axial spondyloarthritis and with psoriasis."Stelara (ustekinumab) / J&JStelara: Expiry of patents ex-US in 2021 (J&J) - Feb 19, 2020 - Annual Report 2019
